This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): ACAM-FLU-A
Description: ACAM-FLU-A is a recombinant vaccine that uses a hepatitis B core protein to deliver M2e, the extracellular domain of the ion channel protein M2. Being highly conserved, M2e is intended to elicit immune responses to all influenza 'A' strains.
Acambis' M2e-based universal flu vaccine contains Antigenics' QS-21 adjuvant. In January 2011, Antigenics changed its name to Agenus.
Deal Structure: ACAM-FLU-A was originally developed by Acambis. In July 2008, Sanofi-aventis announced it reached an agreement with Acambis on the terms of a unanimously recommended cash offer for the entire issued and to be issued share capital of Acambis. The acquisition was completed in September 2008.
Partners: Agenus Inc.
Pink Sheet Weekly Trademark Review Dec. 15, 2015
Additional information available to subscribers only: